logo-loader
Instem PLC

Instem plc - Notice of Capital Markets Day

RNS Number : 7108B
Instem plc
14 June 2021
 

Instem plc

 

("Instem" or "the Company" or "the Group")

 

Notice of Capital Markets Day

 

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that it will be hosting a virtual Capital Markets Day for retail investors on Thursday 01 July 2021.

 

During the event, management will provide greater insight into the business, its ongoing acquisition strategy and its growth potential. The event will include presentations detailing developments in each of the Company's business lines as well as the wider market opportunity. There will be opportunities for attendees to ask questions during the webcast.

 

The session, lasting 2 hours, will be hosted between 14:00 to 16:00 BST welcoming retail investors.

 

If you are interested in attending or have any questions relating to the Capital Markets Day, please contact Walbrook via instem@walbrookpr.com.

 

Institutional Investor Event

The Company will also be hosting a separate virtual Capital Markets Day at the same times on Wednesday 30 June 2021 for Institutional investors. If you are interested in attending please contact kimberley.young@n1singer.com.

 

For further information, please contact:

 

Instem plc

Via Walbrook

Phil Reason, CEO

 

Nigel Goldsmith, CFO

 

 

 

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Peter Steel

Alex Bond

Rachel Hayes

 

 

 

Walbrook Financial PR

+44 (0) 20 7933 8780

Tom Cooper

instem@walbrookpr.com

Nick Rome

Nicholas Johnson

 

 

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.

 

Instem solutions are in use by over 600 customers worldwide, including all the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

 

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform at some stage of their development.

 

To learn more about Instem solutions and its mission, please visit www.instem.com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEAPKFFDKFEFA
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

Instem proves in step with groundbreaking market needs as it posts strong...

Phil Reason, CEO of Instem PLC (AIM:INS), joined Proactive with details of the company's 2022 financial performance. The company grew revenues by 28% and underlying earnings were up 32%. It also said it expected to benefit in 2023 from ‘industry consolidation’. Recent success include...

on 15/5/23

3 min read